# Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia

> **NCT05128162** · PHASE2 · COMPLETED · sponsor: **Kevin Boehnke** · enrollment: 17 (actual)

## Conditions studied

- Fibromyalgia

## Interventions

- **DRUG:** Psilocybin
- **BEHAVIORAL:** Psychotherapy

## Key facts

- **NCT ID:** NCT05128162
- **Lead sponsor:** Kevin Boehnke
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-27
- **Primary completion:** 2024-06-12
- **Final completion:** 2024-06-12
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05128162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05128162, "Open-label Study to Assess the Safety and Efficacy of Psilocybin With Psychotherapy in Adult Participants With Fibromyalgia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05128162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*